Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,256 across all filing types
Latest filing 2026-01-31 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-31 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about the receipt of regulatory permission from the Central Drugs Standard Control Organisation for an additional indication of a pharmaceutical product. The content is an intimation or announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is short (1849 characters) and does not contain financial data or detailed report content. It is an announcement of a regulatory event relevant to stock exchange disclosures, fitting the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-01-31 English
Please find the enclosed letter of the Company in relation to the captioned subject for your reference.
Regulatory Filings
2026-01-31 English
Board Meeting — Financial Results
Regulatory Filings
2026-01-31 English
General Updates
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the resignation of a Non-Executive Director, Ms. Sylvia Lorena Varela Ramon, from AstraZeneca Pharma India Limited. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events or information. The content includes the resignation date, appreciation for the director's contribution, and annexures with details and the resignation letter. There is no financial data, audit information, or report attached. The document is clearly an announcement of a change in the company's board of directors, fitting the category of Board/Management Information (MANG). The document length is short and focused solely on this management change, confirming it is not a full report or other filing type.
2026-01-29 English
Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.
Regulatory Filings
2026-01-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.